Ali S. Alzahrani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ali S. Alzahrani has a total of 356 co-authors. Here are the top co-authors by number of shared publications:
Meshael Alswailem
Department of Molecular Oncology, King Faisal Specialist Hospital & Research Centre
25 shared publicationsHindi Al-Hindi
Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
24 shared publicationsBalgees Alghamdi
Molecular Endocrinology Section, Research and Innovations, King Faisal Specialist Hospital and Research Centre , Riyadh 11211
22 shared publicationsAvaniyapuram Kannan Murugan
Department of Molecular Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
19 shared publications- Yufei Shi
Department of Molecular Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
15 shared publications Ebtesam Qasem
Division of Molecular Endocrinology, Department of Molecular Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia
13 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (12)
Germline AIP variants are rare in sporadic unselected pituitary adenomas
Context: Germline AIP variants are recognized causes of familial isolated pituitary adenoma, associated with young-onset and aggressive pituitary adenomas (PA). In this study, we evaluated the prevalence and phenotype of AIP variants in sporadic PA in the highly consanguineous population of Saudi Arabia. Methods: In this prospective cross-sectional study, 188 non-selected patients (53% males, 44% ≤30-year-old, 80.3% macroadenomas) with PAs underwent Sanger sequencing of all exons and exon–intron boundaries of the AIP gene. We also evaluated all curated AIP variants in a local population database of 18 360 whole-exome sequences. Results: Among 188 successfully sequenced cases, only 2 patients (1.1%) harbored AIP variants, both variants of uncertain significance (VUS). The first was a 17-year-old male with a giant prolactinoma, consistent with the classical AIP-associated phenotype, who had a previously reported variant (NM_003977.4:c.563G>A, p.Arg188Gln). The second was a 60-year-old woman with a gonadotroph macroadenoma, atypical for AIP-related disease, who had a variant (c.767C>T, p.Ser256Phe). Neither tumor showed loss of heterozygosity, repeated twice on carefully selected tumor tissue. Thus, the prevalence of VUS was only 2/188, but of pathogenic/likely pathogenic AIP variants was 0/188 (95% CI, 0-1.9%) overall and 0/151 (95% CI, 0-2.4%) among macroadenomas. The institutional database showed only 8 AIP VUS in 20 unrelated subjects (0.11%). Conclusion: Although this cohort included a high proportion of young patients and macroadenomas, no pathogenic or likely pathogenic AIP variant was found. AIP variants are rare in sporadic PAs in this population, supporting highly selective testing for AIP variants in patients with PA.
- 16 October 2026
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (12)
Open AccessGermline AIP variants are rare in sporadic unselected pituitary adenomas
Context: Germline AIP variants are recognized causes of familial isolated pituitary adenoma, associated with young-onset and aggressive pituitary adenomas (PA). In this study, we evaluated the prevalence and phenotype of AIP variants in sporadic PA in the highly consanguineous population of Saudi Arabia. Methods: In this prospective cross-sectional study, 188 non-selected patients (53% males, 44% ≤30-year-old, 80.3% macroadenomas) with PAs underwent Sanger sequencing of all exons and exon–intron boundaries of the AIP gene. We also evaluated all curated AIP variants in a local population database of 18 360 whole-exome sequences. Results: Among 188 successfully sequenced cases, only 2 patients (1.1%) harbored AIP variants, both variants of uncertain significance (VUS). The first was a 17-year-old male with a giant prolactinoma, consistent with the classical AIP-associated phenotype, who had a previously reported variant (NM_003977.4:c.563G>A, p.Arg188Gln). The second was a 60-year-old woman with a gonadotroph macroadenoma, atypical for AIP-related disease, who had a variant (c.767C>T, p.Ser256Phe). Neither tumor showed loss of heterozygosity, repeated twice on carefully selected tumor tissue. Thus, the prevalence of VUS was only 2/188, but of pathogenic/likely pathogenic AIP variants was 0/188 (95% CI, 0-1.9%) overall and 0/151 (95% CI, 0-2.4%) among macroadenomas. The institutional database showed only 8 AIP VUS in 20 unrelated subjects (0.11%). Conclusion: Although this cohort included a high proportion of young patients and macroadenomas, no pathogenic or likely pathogenic AIP variant was found. AIP variants are rare in sporadic PAs in this population, supporting highly selective testing for AIP variants in patients with PA.
- Open Access
- 15 October 2026
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (12)
Comparison and calibration of the 2025 and 2015 American Thyroid Association recurrence-risk classifications in differentiated thyroid cancer
Context: The 2025 American Thyroid Association (ATA) guidelines maintained the low- and high-risk categories and subdivided the intermediate-risk category of differentiated thyroid cancer (DTC) into low-intermediate and intermediate-high tiers. Objective: To determine whether observed rates of structural disease match the risks the 2025 and 2015 ATA classifications assign, and to compare the two systems. Patients and Methods: All 258 consecutive adults with DTC diagnosed in 2017 were classified under both systems using initial postoperative data. The main outcome was structural disease at any assessment, compared against the guideline-assigned ranges. Results: Sixty-three patients (24.4%) were reclassified, including 52 of 121 (43.0%) low-risk patients upstaged. Thirty-two (12.4%) developed structural disease. Observed 2025 rates were 0.0% (95% CI, 0.0-5.3), 1.5% (0.3-8.0), 15.5% (9.3-24.7), and 47.4% (32.5-62.7) for low, low-intermediate, intermediate-high, and high risk. The low-intermediate interval fell entirely below its assigned 10% to 15% range (P = .013 vs the 10% lower bound); the other categories of both systems were consistent with theirs. No patient upstaged from the 2015 low-risk category developed structural disease. Structural disease later developed in 7 of 14 patients with a biochemically incomplete first response, 2 of 79 indeterminate, and 0 of 129 excellent responses. Discrimination did not differ between the 2 systems (ΔAUC 0.002; 95% CI, −0.031 to 0.036). Conclusion: The 2025 low-intermediate category overestimated recurrence risk in this cohort, and upstaging of low-risk patients identified nobody who developed structural disease. Confirmation in larger multicenter cohorts is needed before these tiers guide treatment intensity.
- 15 October 2026
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (12)
Open AccessComparison and calibration of the 2025 and 2015 American Thyroid Association recurrence-risk classifications in differentiated thyroid cancer
Context: The 2025 American Thyroid Association (ATA) guidelines maintained the low- and high-risk categories and subdivided the intermediate-risk category of differentiated thyroid cancer (DTC) into low-intermediate and intermediate-high tiers. Objective: To determine whether observed rates of structural disease match the risks the 2025 and 2015 ATA classifications assign, and to compare the two systems. Patients and Methods: All 258 consecutive adults with DTC diagnosed in 2017 were classified under both systems using initial postoperative data. The main outcome was structural disease at any assessment, compared against the guideline-assigned ranges. Results: Sixty-three patients (24.4%) were reclassified, including 52 of 121 (43.0%) low-risk patients upstaged. Thirty-two (12.4%) developed structural disease. Observed 2025 rates were 0.0% (95% CI, 0.0-5.3), 1.5% (0.3-8.0), 15.5% (9.3-24.7), and 47.4% (32.5-62.7) for low, low-intermediate, intermediate-high, and high risk. The low-intermediate interval fell entirely below its assigned 10% to 15% range (P = .013 vs the 10% lower bound); the other categories of both systems were consistent with theirs. No patient upstaged from the 2015 low-risk category developed structural disease. Structural disease later developed in 7 of 14 patients with a biochemically incomplete first response, 2 of 79 indeterminate, and 0 of 129 excellent responses. Discrimination did not differ between the 2 systems (ΔAUC 0.002; 95% CI, −0.031 to 0.036). Conclusion: The 2025 low-intermediate category overestimated recurrence risk in this cohort, and upstaging of low-risk patients identified nobody who developed structural disease. Confirmation in larger multicenter cohorts is needed before these tiers guide treatment intensity.
- 1 October 2026
- Published by SAGE Publications in Thyroid®
- Vol. 36 (11) , 1275-1280
Exceptional and Durable Response to Selpercatinib in a Patient with Apparently RET -Negative, HRAS -, and NF1 -Mutated Metastatic Medullary Thyroid Carcinoma
Background: Selpercatinib is approved for RET -mutated medullary thyroid carcinoma (MTC); its activity in tumors without detectable RET alterations is uncertain. Patient Findings: A 50-year-old woman developed rapidly progressive MTC (Ki-67 = 30%) with extensive liver and bone metastases. Because of severe symptomatic progression, selpercatinib was started urgently, off-label, before molecular testing results were available. She had rapid clinical improvement, marked calcitonin and CEA decline, and a remarkable and durable radiographic partial response until the last follow-up (29 months). Summary: Repeated germline and tumor testing [ RET Sanger sequencing, germline whole-exome sequencing, tumor DNA/RNA panel testing, RET Multiplex Ligation-Dependent Probe Amplification (MLPA), tumor whole-genome sequencing] identified no pathogenic or actionable RET variant, indel, copy-number alteration, or fusion. The only somatic alterations found were HRAS p.G13S and truncating NF1 p.R2450*. Conclusions: This remarkable response to selpercatinib in apparently RET -negative MTC is hypothesis generating and requires confirmation. HRAS / NF1 co-alteration supports RAS/MAPK activation but does not explain sensitivity to selective RET inhibition.
- 1 October 2026
- Published by SAGE Publications in Thyroid®
- Vol. 36 (11) , 1275-1280
Exceptional and Durable Response to Selpercatinib in a Patient with Apparently RET -Negative, HRAS -, and NF1 -Mutated Metastatic Medullary Thyroid Carcinoma
Background: Selpercatinib is approved for RET -mutated medullary thyroid carcinoma (MTC); its activity in tumors without detectable RET alterations is uncertain. Patient Findings: A 50-year-old woman developed rapidly progressive MTC (Ki-67 = 30%) with extensive liver and bone metastases. Because of severe symptomatic progression, selpercatinib was started urgently, off-label, before molecular testing results were available. She had rapid clinical improvement, marked calcitonin and CEA decline, and a remarkable and durable radiographic partial response until the last follow-up (29 months). Summary: Repeated germline and tumor testing [ RET Sanger sequencing, germline whole-exome sequencing, tumor DNA/RNA panel testing, RET Multiplex Ligation-Dependent Probe Amplification (MLPA), tumor whole-genome sequencing] identified no pathogenic or actionable RET variant, indel, copy-number alteration, or fusion. The only somatic alterations found were HRAS p.G13S and truncating NF1 p.R2450*. Conclusions: This remarkable response to selpercatinib in apparently RET -negative MTC is hypothesis generating and requires confirmation. HRAS / NF1 co-alteration supports RAS/MAPK activation but does not explain sensitivity to selective RET inhibition.
- Open Access
- 25 September 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1925714
Case Report: Pallister-Hall syndrome diagnosed in adulthood during evaluation of recurrent hypoglycemia
Introduction: Pallister-Hall syndrome (PHS) is a rare autosomal dominant disorder caused by pathogenic variants in GLI3 gene. It is characterized by variable combinations of hypothalamic hamartoma, polydactyly, bifid epiglottis, renal and genitourinary abnormalities, imperforate anus, and pituitary dysfunction. Most cases are recognized during infancy or childhood; adult presentation is uncommon and hypoglycemia is not an established manifestation of PHS. Case description: A 26-year-old man with obesity and well-controlled hypertension was referred for evaluation of recurrent fasting and postprandial hypoglycemia associated with intermittent brief loss of consciousness. Physical examination revealed class III obesity, acanthosis nigricans, hand polydactyly, and a history of surgically removed extra toe in childhood. Family history was remarkable for polydactyly affecting the mother and multiple maternal relatives. Biochemical evaluation demonstrated recurrent hypoglycemia with inappropriately unsuppressed insulin and C-peptide concentrations, compatible with endogenous hyperinsulinemic hypoglycemia, during both prolonged fasting and mixed-meal testing. Abdominal magnetic resonance imaging showed no pancreatic lesion but an atrophic right kidney and hepatic steatosis. Whole-exome sequencing identified a heterozygous GLI3 deletion with frameshift variant (NM_000168.6:c.2059del, p.(Glu687LysfsTer6)), confirming the diagnosis of PHS. Subsequent investigations demonstrated a hypothalamic hamartoma and partially bifid epiglottis, further confirming the diagnosis of PHS. The patient was referred for multidisciplinary management and genetic counseling. Conclusion: This case highlights an unusual late presentation of PHS with recurrent hypoglycemia, severe obesity, and episodic loss of consciousness and demonstrates the multi-systemic involvement in PHS. It emphasizes the importance of careful phenotypic assessment and the value of genetic testing in establishing a unifying diagnosis in complex presentations.
- 25 September 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1925714
Open AccessCase Report: Pallister-Hall syndrome diagnosed in adulthood during evaluation of recurrent hypoglycemia
Introduction: Pallister-Hall syndrome (PHS) is a rare autosomal dominant disorder caused by pathogenic variants in GLI3 gene. It is characterized by variable combinations of hypothalamic hamartoma, polydactyly, bifid epiglottis, renal and genitourinary abnormalities, imperforate anus, and pituitary dysfunction. Most cases are recognized during infancy or childhood; adult presentation is uncommon and hypoglycemia is not an established manifestation of PHS. Case description: A 26-year-old man with obesity and well-controlled hypertension was referred for evaluation of recurrent fasting and postprandial hypoglycemia associated with intermittent brief loss of consciousness. Physical examination revealed class III obesity, acanthosis nigricans, hand polydactyly, and a history of surgically removed extra toe in childhood. Family history was remarkable for polydactyly affecting the mother and multiple maternal relatives. Biochemical evaluation demonstrated recurrent hypoglycemia with inappropriately unsuppressed insulin and C-peptide concentrations, compatible with endogenous hyperinsulinemic hypoglycemia, during both prolonged fasting and mixed-meal testing. Abdominal magnetic resonance imaging showed no pancreatic lesion but an atrophic right kidney and hepatic steatosis. Whole-exome sequencing identified a heterozygous GLI3 deletion with frameshift variant (NM_000168.6:c.2059del, p.(Glu687LysfsTer6)), confirming the diagnosis of PHS. Subsequent investigations demonstrated a hypothalamic hamartoma and partially bifid epiglottis, further confirming the diagnosis of PHS. The patient was referred for multidisciplinary management and genetic counseling. Conclusion: This case highlights an unusual late presentation of PHS with recurrent hypoglycemia, severe obesity, and episodic loss of consciousness and demonstrates the multi-systemic involvement in PHS. It emphasizes the importance of careful phenotypic assessment and the value of genetic testing in establishing a unifying diagnosis in complex presentations.
- Open Access
- 23 September 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1948006
Clinical features, comorbidities, and therapeutic outcomes of Cushing syndrome: a retrospective multicenter study from Saudi Arabia
Purpose: Cushing syndrome (CS) is associated with significant morbidity and mortality, but data from the Middle East, including Saudi Arabia, are limited. This study aimed to characterize the demographics, clinical features, comorbidities, diagnostic findings, treatments, and outcomes in a Saudi Arabian multicenter tertiary-referral cohort. Methods: In this retrospective multicenter study, 146 patients with confirmed CS were included. Demographics, clinical features, laboratory and imaging results, treatments, and outcomes were collected and analyzed according to etiological subtype. Results: Among 146 patients (114 women, 32 men; mean age at last recorded follow-up or data abstraction, 42.2 ± 14.7 years), pituitary CS was the most common etiology (61.0%). The mean diagnostic delay was 7.5 years (median 5 years). Hypertension (62.3%) and dysglycemia (67.1%) were prevalent. Among the 88 patients who underwent bone mineral density assessment, 71.6% had abnormal bone health; this selected-subgroup estimate should not be generalized to the entire cohort. Hypokalemia was frequent in ectopic CS (84.6%). Treatment was etiology-specific: 85.4% of the patients with pituitary CS underwent transsphenoidal surgery (TSS), and 87.9% of patients with adrenal CS who underwent adrenalectomy had a unilateral procedure. Crude mortality was 5.1% (7/138 patients with known vital status), remission was documented in 66.9% (93/139 with recorded outcomes), and recurrence after a documented remission occurred in 12 patients. Conclusion: In this Saudi Arabian multicenter tertiary-referral cohort, CS predominantly affects women and is most frequently attributable to pituitary CS. Diagnostic delay remains prolonged despite advances in diagnosis and management. Descriptive treatment outcomes were broadly consistent with international experience; crude mortality was 5.1% among patients with known vital status.
- 23 September 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1948006
Open AccessClinical features, comorbidities, and therapeutic outcomes of Cushing syndrome: a retrospective multicenter study from Saudi Arabia
Purpose: Cushing syndrome (CS) is associated with significant morbidity and mortality, but data from the Middle East, including Saudi Arabia, are limited. This study aimed to characterize the demographics, clinical features, comorbidities, diagnostic findings, treatments, and outcomes in a Saudi Arabian multicenter tertiary-referral cohort. Methods: In this retrospective multicenter study, 146 patients with confirmed CS were included. Demographics, clinical features, laboratory and imaging results, treatments, and outcomes were collected and analyzed according to etiological subtype. Results: Among 146 patients (114 women, 32 men; mean age at last recorded follow-up or data abstraction, 42.2 ± 14.7 years), pituitary CS was the most common etiology (61.0%). The mean diagnostic delay was 7.5 years (median 5 years). Hypertension (62.3%) and dysglycemia (67.1%) were prevalent. Among the 88 patients who underwent bone mineral density assessment, 71.6% had abnormal bone health; this selected-subgroup estimate should not be generalized to the entire cohort. Hypokalemia was frequent in ectopic CS (84.6%). Treatment was etiology-specific: 85.4% of the patients with pituitary CS underwent transsphenoidal surgery (TSS), and 87.9% of patients with adrenal CS who underwent adrenalectomy had a unilateral procedure. Crude mortality was 5.1% (7/138 patients with known vital status), remission was documented in 66.9% (93/139 with recorded outcomes), and recurrence after a documented remission occurred in 12 patients. Conclusion: In this Saudi Arabian multicenter tertiary-referral cohort, CS predominantly affects women and is most frequently attributable to pituitary CS. Diagnostic delay remains prolonged despite advances in diagnosis and management. Descriptive treatment outcomes were broadly consistent with international experience; crude mortality was 5.1% among patients with known vital status.
- 21 August 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Octreotide as adjunctive therapy for catecholamine-secreting pheochromocytoma and paraganglioma
Context: Catecholamine-secreting pheochromocytomas and paragangliomas (PPGLs) can be difficult to stabilize before surgery or during follow-up. Somatostatin-receptor expression provides a rationale for octreotide therapy, but clinical evidence is limited. Objective: To evaluate clinical, biochemical, hemodynamic, metabolic, and perioperative outcomes associated with octreotide treatment in catecholamine-secreting PPGLs. Methods: We retrospectively studied 27 consecutive patients with PPGLs treated with octreotide at 2 referral centers in Muscat, Oman, between January 2012 and March 2026. Primary outcomes were clinical, hemodynamic, and biochemical responses; secondary outcomes included glycemic, surgical, and follow-up outcomes. Results: Twenty-seven patients were included (70.4% female; mean age, 50.3 ± 22.2 years); 14 had paraganglioma and 13 pheochromocytoma. All received long-acting octreotide, and 10 also received short-acting octreotide. Median plasma norepinephrine decreased from 6723 to 1901 pmol/L (P < .0001). Epinephrine, dopamine, and chromogranin A also decreased significantly. The mean blood pressure decreased from 154.8/93.5 to 123.0/75.3 mmHg (n = 24; P = .0003 for systolic and P = .0006 for diastolic pressure), and mean HbA1c decreased from 8.6 ± 2.4% to 6.2 ± 0.8% among patients with diabetes (n = 11; P = .005). Seventeen patients underwent uneventful surgical resection. During a median follow-up of 3 years, only 1 non–PPGL-related death occurred. Conclusions: Octreotide treatment was associated with biochemical, hemodynamic, and metabolic improvement and may serve as a useful adjunct in selected patients, particularly as a bridge to surgery and during perioperative preparation.
- 21 August 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Octreotide as adjunctive therapy for catecholamine-secreting pheochromocytoma and paraganglioma
Context: Catecholamine-secreting pheochromocytomas and paragangliomas (PPGLs) can be difficult to stabilize before surgery or during follow-up. Somatostatin-receptor expression provides a rationale for octreotide therapy, but clinical evidence is limited. Objective: To evaluate clinical, biochemical, hemodynamic, metabolic, and perioperative outcomes associated with octreotide treatment in catecholamine-secreting PPGLs. Methods: We retrospectively studied 27 consecutive patients with PPGLs treated with octreotide at 2 referral centers in Muscat, Oman, between January 2012 and March 2026. Primary outcomes were clinical, hemodynamic, and biochemical responses; secondary outcomes included glycemic, surgical, and follow-up outcomes. Results: Twenty-seven patients were included (70.4% female; mean age, 50.3 ± 22.2 years); 14 had paraganglioma and 13 pheochromocytoma. All received long-acting octreotide, and 10 also received short-acting octreotide. Median plasma norepinephrine decreased from 6723 to 1901 pmol/L (P < .0001). Epinephrine, dopamine, and chromogranin A also decreased significantly. The mean blood pressure decreased from 154.8/93.5 to 123.0/75.3 mmHg (n = 24; P = .0003 for systolic and P = .0006 for diastolic pressure), and mean HbA1c decreased from 8.6 ± 2.4% to 6.2 ± 0.8% among patients with diabetes (n = 11; P = .005). Seventeen patients underwent uneventful surgical resection. During a median follow-up of 3 years, only 1 non–PPGL-related death occurred. Conclusions: Octreotide treatment was associated with biochemical, hemodynamic, and metabolic improvement and may serve as a useful adjunct in selected patients, particularly as a bridge to surgery and during perioperative preparation.
- Open Access
- 14 August 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1850762
Case Report: Three pathogenic molecular findings in a patient with myotonia congenita, pseudohypoparathyroidism, and a glaucoma-suspect phenotype
Background: The presence of multiple rare Mendelian disorders in a single patient may mask clinical recognition when phenotypes overlap. We describe a patient with longstanding myotonia congenita due to a CLCN1 variant in whom an incidental discovery of severe hypocalcemia led to the diagnosis of GNAS -related pseudohypoparathyroidism (PHP). Exome reanalysis also identified an incidental homozygous pathogenic CYP1B1 variant associated with autosomal recessive glaucoma. Case presentation: A 23-year-old man born to consanguineous parents was referred for management of chronic myotonia congenita, manifested by delayed motor milestones, frequent falls, contractures, and muscle hypertrophy. Electrophysiological assessment demonstrated myotonic discharges, and whole-exome sequencing (WES) identified a homozygous CLCN1 splice-site variant (NM_000083.3:c.1167-10T>C) known to cause myotonia congenita. During subsequent evaluation, he was found to have severe hypocalcemia, hyperphosphatemia, markedly elevated parathyroid hormone, basal ganglia and dentate calcifications, brachydactyly, subcutaneous calcifications, and mild hypothyroidism, raising suspicion for PHP. Genetic and ophthalmologic findings: Reanalysis of WES data demonstrated a heterozygous frameshift GNAS variant (NM_080425.4:c.2494_2497delCTGA) and a homozygous CYP1B1 variant (NM_000104.4:c.182G>A; p.Gly61Glu) in addition to the CLCN1 defect. Sanger sequencing confirmed all three variants. The CYP1B1 finding prompted glaucoma-specialist evaluation. Visual acuity was 20/22 in the right eye and 20/25 in the left eye; intraocular pressures were 8 and 12 mmHg, respectively. The corneas were clear, cup-to-disc ratios were 0.4 and 0.5, and average retinal nerve fiber layer thicknesses were 74 and 75 µm. No definite glaucomatous damage was identified, and the patient was classified as a glaucoma suspect. After treatment with calcium, calcitriol, and ergocalciferol, serum calcium improved, parathyroid hormone levels declined, creatine kinase normalized, and the patient reported improved muscle stiffness and function. Conclusion: This case demonstrates two clinically expressed Mendelian disorders together with a third actionable molecular finding. It highlights the importance of careful phenotyping, molecular testing, and cautious genotype-phenotype interpretation, particularly in consanguineous populations.
- 14 August 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1850762
Open AccessCase Report: Three pathogenic molecular findings in a patient with myotonia congenita, pseudohypoparathyroidism, and a glaucoma-suspect phenotype
Background: The presence of multiple rare Mendelian disorders in a single patient may mask clinical recognition when phenotypes overlap. We describe a patient with longstanding myotonia congenita due to a CLCN1 variant in whom an incidental discovery of severe hypocalcemia led to the diagnosis of GNAS -related pseudohypoparathyroidism (PHP). Exome reanalysis also identified an incidental homozygous pathogenic CYP1B1 variant associated with autosomal recessive glaucoma. Case presentation: A 23-year-old man born to consanguineous parents was referred for management of chronic myotonia congenita, manifested by delayed motor milestones, frequent falls, contractures, and muscle hypertrophy. Electrophysiological assessment demonstrated myotonic discharges, and whole-exome sequencing (WES) identified a homozygous CLCN1 splice-site variant (NM_000083.3:c.1167-10T>C) known to cause myotonia congenita. During subsequent evaluation, he was found to have severe hypocalcemia, hyperphosphatemia, markedly elevated parathyroid hormone, basal ganglia and dentate calcifications, brachydactyly, subcutaneous calcifications, and mild hypothyroidism, raising suspicion for PHP. Genetic and ophthalmologic findings: Reanalysis of WES data demonstrated a heterozygous frameshift GNAS variant (NM_080425.4:c.2494_2497delCTGA) and a homozygous CYP1B1 variant (NM_000104.4:c.182G>A; p.Gly61Glu) in addition to the CLCN1 defect. Sanger sequencing confirmed all three variants. The CYP1B1 finding prompted glaucoma-specialist evaluation. Visual acuity was 20/22 in the right eye and 20/25 in the left eye; intraocular pressures were 8 and 12 mmHg, respectively. The corneas were clear, cup-to-disc ratios were 0.4 and 0.5, and average retinal nerve fiber layer thicknesses were 74 and 75 µm. No definite glaucomatous damage was identified, and the patient was classified as a glaucoma suspect. After treatment with calcium, calcitriol, and ergocalciferol, serum calcium improved, parathyroid hormone levels declined, creatine kinase normalized, and the patient reported improved muscle stiffness and function. Conclusion: This case demonstrates two clinically expressed Mendelian disorders together with a third actionable molecular finding. It highlights the importance of careful phenotyping, molecular testing, and cautious genotype-phenotype interpretation, particularly in consanguineous populations.
- 3 August 2026
- Published by SAGE Publications in Thyroid®
- Vol. 36 (9) , 940-950
Prognostic Stratification of Brain Metastases from Nonanaplastic Follicular Cell–Derived Thyroid Carcinoma: Results of an International Multicenter Retrospective Study
Background: Brain metastases (BMs) from nonanaplastic follicular cell–derived thyroid carcinoma (hereinafter referred to as non-ATC) are rare and not well characterized, with limited evidence guiding treatment and prognostic stratification. We aimed to describe clinical features, treatment patterns, and outcomes of patients with BMs from non-ATC and to develop and validate a disease-specific prognostic score. Methods: This retrospective international multicenter study included adults with histologically confirmed non-ATC and radiologically documented BMs treated at 19 tertiary referral centers. Clinical, radiological, treatment, and outcome data were collected. Independent predictors of progression-free survival (PFS) and overall survival (OS) were analyzed using Cox regression, and variables identified were used to develop a disease-specific Graded Prognostic Assessment (non-ATC GPA), exploratorily assessed in an independent SEER cohort. Results: A total of 189 patients were included; median age at BM diagnosis was 59 years (interquartile range [IQR] 48–67). First-line BM treatments included stereotactic radiosurgery (27.0%), neurosurgery (23.8%), whole-brain radiotherapy (18.5%), and best supportive care (10.6%). Median PFS was 7.0 months (IQR: 2.9–22.4), and median OS was 15.0 months (IQR: 4.0–38.4). Independent predictors of shorter OS were age >75 years, Eastern Cooperative Oncology Group performance status ≥2, papillary histology, extracranial metastases, and ≥4 BM. The GPA stratified patients into four prognostic groups with median OS ranging from 72.6 months in the highest-score group to 3.7 months in the lowest. An exploratory SEER-based assessment showed survival differences across adapted prognostic groups ( p = 0.036), although this analysis was limited by the absence of all key GPA variables. Conclusions: BMs from non-ATC are associated with poor survival and marked prognostic heterogeneity. The proposed GPA may provide a useful framework for prognostic stratification, pending further validation in independent datasets to support individualized management.
- 3 August 2026
- Published by SAGE Publications in Thyroid®
- Vol. 36 (9) , 940-950
Prognostic Stratification of Brain Metastases from Nonanaplastic Follicular Cell–Derived Thyroid Carcinoma: Results of an International Multicenter Retrospective Study
Background: Brain metastases (BMs) from nonanaplastic follicular cell–derived thyroid carcinoma (hereinafter referred to as non-ATC) are rare and not well characterized, with limited evidence guiding treatment and prognostic stratification. We aimed to describe clinical features, treatment patterns, and outcomes of patients with BMs from non-ATC and to develop and validate a disease-specific prognostic score. Methods: This retrospective international multicenter study included adults with histologically confirmed non-ATC and radiologically documented BMs treated at 19 tertiary referral centers. Clinical, radiological, treatment, and outcome data were collected. Independent predictors of progression-free survival (PFS) and overall survival (OS) were analyzed using Cox regression, and variables identified were used to develop a disease-specific Graded Prognostic Assessment (non-ATC GPA), exploratorily assessed in an independent SEER cohort. Results: A total of 189 patients were included; median age at BM diagnosis was 59 years (interquartile range [IQR] 48–67). First-line BM treatments included stereotactic radiosurgery (27.0%), neurosurgery (23.8%), whole-brain radiotherapy (18.5%), and best supportive care (10.6%). Median PFS was 7.0 months (IQR: 2.9–22.4), and median OS was 15.0 months (IQR: 4.0–38.4). Independent predictors of shorter OS were age >75 years, Eastern Cooperative Oncology Group performance status ≥2, papillary histology, extracranial metastases, and ≥4 BM. The GPA stratified patients into four prognostic groups with median OS ranging from 72.6 months in the highest-score group to 3.7 months in the lowest. An exploratory SEER-based assessment showed survival differences across adapted prognostic groups ( p = 0.036), although this analysis was limited by the absence of all key GPA variables. Conclusions: BMs from non-ATC are associated with poor survival and marked prognostic heterogeneity. The proposed GPA may provide a useful framework for prognostic stratification, pending further validation in independent datasets to support individualized management.
- Open Access
- 28 May 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1834727
Familial glucocorticoid deficiency due to a novel TXNRD2 variant: expanding the spectrum of a rare genetic cause
Background: Familial glucocorticoid deficiency (FGD) is a rare autosomal recessive disorder characterized by isolated cortisol deficiency and elevated adrenocorticotropic hormone (ACTH) levels. Variants in TXNRD2 , which encodes mitochondrial thioredoxin reductase 2, have recently been implicated in FGD; however, the phenotypic and mutational spectrum remain extremely limited. Methods: Whole-genome sequencing (WGS) was performed in a proband from a Saudi family who presented in early childhood with clinical and biochemical features consistent with FGD (Low basal and stimulated cortisol of < 5 nmol/l and extremely elevated ACTH levels of > 2500 pg/ml) and seizure disorder requiring medical treatment and with basal ganglia changes noted on brain MRI at presentation. WGS identified a novel likely pathogenic TXNRD2 variant with no other potential variant in FGD-associated genes. Population frequency, segregation analysis, evolutionary conservation, and in silico pathogenicity predictions were assessed for the identified variant. Results: WGS identified a novel missense homozygous TXNRD2 (NM_001282512) variant (c.575C>T (p.Pro192Leu) in the proband, and in the heterozygous state in both parents, supporting autosomal recessive inheritance. This variant has not been reported in a local population database of > 18000 exomes, is extremely rare in international population databases (minor allele frequency 0.00000479), and affects a highly conserved residue. The variant was consistently predicted by multiple in silico tools to have deleterious effects on protein structure and function. No pathogenic, likely pathogenic, or VUS was found in other genes involved in FGD, including MC2R, MRAP, STAR, CYP11A1, NNT, MCM4, or SGPL1. Conclusion: This report adds another patient with a novel variant to the few previously described patients and expands the genetic spectrum of the very rare TXNRD2 -associated FGD, supporting the role of mitochondrial redox dysregulation in adrenal insufficiency.
- 28 May 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1834727
Open AccessFamilial glucocorticoid deficiency due to a novel TXNRD2 variant: expanding the spectrum of a rare genetic cause
Background: Familial glucocorticoid deficiency (FGD) is a rare autosomal recessive disorder characterized by isolated cortisol deficiency and elevated adrenocorticotropic hormone (ACTH) levels. Variants in TXNRD2 , which encodes mitochondrial thioredoxin reductase 2, have recently been implicated in FGD; however, the phenotypic and mutational spectrum remain extremely limited. Methods: Whole-genome sequencing (WGS) was performed in a proband from a Saudi family who presented in early childhood with clinical and biochemical features consistent with FGD (Low basal and stimulated cortisol of < 5 nmol/l and extremely elevated ACTH levels of > 2500 pg/ml) and seizure disorder requiring medical treatment and with basal ganglia changes noted on brain MRI at presentation. WGS identified a novel likely pathogenic TXNRD2 variant with no other potential variant in FGD-associated genes. Population frequency, segregation analysis, evolutionary conservation, and in silico pathogenicity predictions were assessed for the identified variant. Results: WGS identified a novel missense homozygous TXNRD2 (NM_001282512) variant (c.575C>T (p.Pro192Leu) in the proband, and in the heterozygous state in both parents, supporting autosomal recessive inheritance. This variant has not been reported in a local population database of > 18000 exomes, is extremely rare in international population databases (minor allele frequency 0.00000479), and affects a highly conserved residue. The variant was consistently predicted by multiple in silico tools to have deleterious effects on protein structure and function. No pathogenic, likely pathogenic, or VUS was found in other genes involved in FGD, including MC2R, MRAP, STAR, CYP11A1, NNT, MCM4, or SGPL1. Conclusion: This report adds another patient with a novel variant to the few previously described patients and expands the genetic spectrum of the very rare TXNRD2 -associated FGD, supporting the role of mitochondrial redox dysregulation in adrenal insufficiency.
- Open Access
- 15 April 2026
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (6)
SDHB -associated paraganglioma in Saudi Arabia: High metastatic risk linked to a likely founder mutation
Context: SDHB-related pheochromocytoma and paraganglioma (PPGL) are associated with a high risk of metastasis. Minimal data are available on these genetically based tumors from the Middle East. Objective: To characterize the phenotype, genotype, and outcome of SDHB-associated PPGLs in Saudi Arabia. Methods: We retrospectively reviewed a cohort of 37 patients with SDHB-associated PPGL. DNA was isolated from peripheral blood samples, and genetic testing was performed using whole-exome sequencing (WES) and confirmed by Sanger sequencing. Results: We identified 37 patients with SDHB mutations, including 14 (37.8%) females and 23 (62.2%) males, with a median age at diagnosis of 28 years (range, 6-49). Nineteen patients (51.4%) had a positive family history of PPGL, and 18 (48.6%) were apparently sporadic but tested positive for SDHB mutations. The most common presentation was hyperadrenergic symptoms (54%), and the most common tumor location was the upper abdomen (45.9%). The most common SDHB mutation (likely a founder mutation) was the truncating mutation c.268T>C (p.R90*), which occurred in 23/37 patients (62%). This mutation was associated with high rates of locally invasive and/or distant metastasis (56.5%) and mortality (21.7%). At a median follow-up of 7 years (IQR 3.5-15), only 10 patients (27%) achieved remission, 7 (18.9%) died due to PPGL, one patient died due to leukemia, and 19 patients (51.4%) continued to have evidence of locally invasive or metastatic disease. Conclusion: In this Middle Eastern cohort, SDHB-associated PPGLs were characterized by high rates of locally invasive or metastatic disease, frequently associated with a possible founder mutation (p.R90*), and substantial mortality.
- 15 April 2026
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (6)
Open AccessSDHB -associated paraganglioma in Saudi Arabia: High metastatic risk linked to a likely founder mutation
Context: SDHB-related pheochromocytoma and paraganglioma (PPGL) are associated with a high risk of metastasis. Minimal data are available on these genetically based tumors from the Middle East. Objective: To characterize the phenotype, genotype, and outcome of SDHB-associated PPGLs in Saudi Arabia. Methods: We retrospectively reviewed a cohort of 37 patients with SDHB-associated PPGL. DNA was isolated from peripheral blood samples, and genetic testing was performed using whole-exome sequencing (WES) and confirmed by Sanger sequencing. Results: We identified 37 patients with SDHB mutations, including 14 (37.8%) females and 23 (62.2%) males, with a median age at diagnosis of 28 years (range, 6-49). Nineteen patients (51.4%) had a positive family history of PPGL, and 18 (48.6%) were apparently sporadic but tested positive for SDHB mutations. The most common presentation was hyperadrenergic symptoms (54%), and the most common tumor location was the upper abdomen (45.9%). The most common SDHB mutation (likely a founder mutation) was the truncating mutation c.268T>C (p.R90*), which occurred in 23/37 patients (62%). This mutation was associated with high rates of locally invasive and/or distant metastasis (56.5%) and mortality (21.7%). At a median follow-up of 7 years (IQR 3.5-15), only 10 patients (27%) achieved remission, 7 (18.9%) died due to PPGL, one patient died due to leukemia, and 19 patients (51.4%) continued to have evidence of locally invasive or metastatic disease. Conclusion: In this Middle Eastern cohort, SDHB-associated PPGLs were characterized by high rates of locally invasive or metastatic disease, frequently associated with a possible founder mutation (p.R90*), and substantial mortality.